Company intelligence / Profile preview

Ourself

Carlsbad, California, United States

Ownership: Private
Development stage: Other

Overview

Ourself has published clinical data demonstrating that its Tiered-Release Vesicles™ delivery technology can deliver large bioactive molecules into the epidermis and dermis[3]. In clinical studies, 92% of users reported skin felt more hydrated and supple after 2 weeks[4], and the Lip Filler product showed results in 3 weeks with 59 participants[4]. The company has 8+ filed and issued patents[4] and received clinical validation published in Dermatologic Surgery journal in December 2024[3].

Therapeutic areas: Dermatology
Modalities: PeptidesTopical delivery system
Industry: Non-Drug Biotech

Beyond the preview

Go deeper on Ourself.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ourself.

Explore the full profile